Literature DB >> 82733

Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia.

T C Pearson, G Wetherley-Mein.   

Abstract

The relations between the incidence of vascular occlusive episodes and packed-cell volume (P.C.V) and platelet-count in patients with primary proliferative polycythaemia were determined retrospectively in patients treated by venesection with or without chemotherapy. The incidence of occlusive episodes correlated positively with P.C.V. level. The risk of vascular occlusive episodes was increased at moderately increased P.C.V. levels and the optimum P.C.V. level was rather lower than is often assumed. There was no statistically significant association between platelet-count, either alone or in combination with raised P.C.V., and incidence of vascular occlusion, though, episodes of occlusion were 1.5 times more common with platelet-counts above 400 x 10(9)/l. The results of this study indicate that P.C.V. should be maintained at less than 0.45 and the platelet-count at less than 400 x 10(9)/l in primary proliferative polycythaemia.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 82733     DOI: 10.1016/s0140-6736(78)92098-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  60 in total

Review 1.  Current applications of therapeutic phlebotomy.

Authors:  Tarek Bou Assi; Elizabeth Baz
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

2.  Treatment of polycythemia vera by isovolemic large-volume erythrocytapheresis.

Authors:  U Kaboth; K W Rumpf; T Lipp; J Bigge; M Nauck; J H Beyer; W Seyde; W Kaboth
Journal:  Klin Wochenschr       Date:  1990-01-04

3.  High hematocrit as a risk factor for venous thrombosis. Cause or innocent bystander?

Authors:  Anja J M Schreijer; Pieter H Reitsma; Suzanne C Cannegieter
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

4.  New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches.

Authors:  Michal Bar-Natan; Ronald Hoffman
Journal:  Haematologica       Date:  2019-01       Impact factor: 9.941

5.  Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.

Authors:  Malin Hultcrantz; Sigurdur Yngvi Kristinsson; Therese M-L Andersson; Ola Landgren; Sandra Eloranta; Asa Rangert Derolf; Paul W Dickman; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

Review 6.  New Therapeutic Approaches in Polycythemia Vera.

Authors:  Lorenzo Falchi; Kate J Newberry; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

7.  Hematocrit and risk of venous thromboembolism in a general population. The Tromso study.

Authors:  Sigrid K Braekkan; Ellisiv B Mathiesen; Inger Njølstad; Tom Wilsgaard; John-Bjarne Hansen
Journal:  Haematologica       Date:  2009-10-14       Impact factor: 9.941

Review 8.  Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

Authors:  Aziz Nazha; Aaron T Gerds
Journal:  Oncologist       Date:  2016-03-14

Review 9.  Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.

Authors:  Alessandro M Vannucchi
Journal:  Intern Emerg Med       Date:  2009-09-30       Impact factor: 3.397

Review 10.  The treatment of polycythaemia vera: an update in the JAK2 era.

Authors:  G Finazzi; T Barbui
Journal:  Intern Emerg Med       Date:  2007-03-31       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.